JP2022511673A5 - - Google Patents
Info
- Publication number
- JP2022511673A5 JP2022511673A5 JP2021523904A JP2021523904A JP2022511673A5 JP 2022511673 A5 JP2022511673 A5 JP 2022511673A5 JP 2021523904 A JP2021523904 A JP 2021523904A JP 2021523904 A JP2021523904 A JP 2021523904A JP 2022511673 A5 JP2022511673 A5 JP 2022511673A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- patient
- administration
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862755674P | 2018-11-05 | 2018-11-05 | |
| US62/755,674 | 2018-11-05 | ||
| PCT/US2019/059822 WO2020097045A1 (en) | 2018-11-05 | 2019-11-05 | Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022511673A JP2022511673A (ja) | 2022-02-01 |
| JP2022511673A5 true JP2022511673A5 (https=) | 2022-11-14 |
Family
ID=70460237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523904A Withdrawn JP2022511673A (ja) | 2018-11-05 | 2019-11-05 | 運動障害を処置するためのガボキサドール、ガナキソロンおよびアロプレグナノロンの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200138785A1 (https=) |
| EP (1) | EP3860595A4 (https=) |
| JP (1) | JP2022511673A (https=) |
| KR (1) | KR20210087952A (https=) |
| CN (1) | CN113260362A (https=) |
| AU (1) | AU2019377074A1 (https=) |
| CA (1) | CA3118688A1 (https=) |
| IL (1) | IL282189A (https=) |
| MX (1) | MX2021005291A (https=) |
| WO (1) | WO2020097045A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117801047B (zh) * | 2023-01-19 | 2024-12-20 | 北京华睿鼎信科技有限公司 | 神经甾体衍生物及其用途 |
| CN116077470A (zh) * | 2023-02-06 | 2023-05-09 | 青岛润昕德生物医药有限公司 | 一种加奈索酮制剂及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070032553A1 (en) * | 2003-09-10 | 2007-02-08 | Mckernan Ruth | Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
| US7858609B2 (en) * | 2005-11-28 | 2010-12-28 | Marinus Pharmaceuticals | Solid ganaxolone formulations and methods for the making and use thereof |
| US9629853B2 (en) * | 2014-05-21 | 2017-04-25 | Wisconsin Alumni Research Foundation | Uses of ganaxolone |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CA2973140C (en) * | 2015-02-06 | 2025-09-16 | Marinus Pharmaceuticals, Inc. | Intravenous Ganaxolone Formulations and Their Use in the Treatment of Status Epilepticus and Other Epileptic Disorders |
| US20170348232A1 (en) * | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
| DK3364993T3 (da) * | 2015-10-22 | 2023-01-09 | Cavion Inc | Fremgangsmåder til behandling af angelman syndrom |
| KR20240157128A (ko) * | 2016-03-08 | 2024-10-31 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| EP3481387A4 (en) * | 2016-08-11 | 2020-04-08 | Ovid Therapeutics Inc | METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES |
-
2019
- 2019-11-05 JP JP2021523904A patent/JP2022511673A/ja not_active Withdrawn
- 2019-11-05 MX MX2021005291A patent/MX2021005291A/es unknown
- 2019-11-05 EP EP19882868.3A patent/EP3860595A4/en not_active Withdrawn
- 2019-11-05 KR KR1020217014795A patent/KR20210087952A/ko not_active Withdrawn
- 2019-11-05 AU AU2019377074A patent/AU2019377074A1/en not_active Abandoned
- 2019-11-05 WO PCT/US2019/059822 patent/WO2020097045A1/en not_active Ceased
- 2019-11-05 US US16/674,601 patent/US20200138785A1/en not_active Abandoned
- 2019-11-05 CA CA3118688A patent/CA3118688A1/en active Pending
- 2019-11-05 CN CN201980087887.3A patent/CN113260362A/zh active Pending
-
2021
- 2021-04-08 IL IL282189A patent/IL282189A/en unknown
- 2021-12-21 US US17/558,195 patent/US20220110917A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520189A5 (https=) | ||
| JP2018514534A5 (https=) | ||
| CA2588296A1 (en) | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease | |
| JP2022544711A5 (https=) | ||
| TW202300139A (zh) | γ-羟基丁酸衍生物的聯合釋放製劑的藥代動力學 | |
| JP2022511673A5 (https=) | ||
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| CN107137417B (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2016505050A5 (https=) | ||
| JP2022519007A5 (https=) | ||
| JP2019507786A5 (https=) | ||
| IL272834B1 (en) | Compositions of amantadine, their preparation, and methods of use | |
| JP2021514380A5 (ja) | 筋障害及び骨障害を処置するための化合物及び組成物 | |
| JP2020506930A5 (https=) | ||
| MX2021008208A (es) | Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi. | |
| JP2021536506A5 (https=) | ||
| US20160082026A1 (en) | Ganglioside Transmucosal Formulations | |
| JP2019535830A5 (https=) | ||
| JP2022518527A5 (https=) | ||
| JP2022504435A5 (https=) | ||
| JP7527662B2 (ja) | ピモジドとメトトレキサートの医薬組成物、及びその使用 | |
| JP2024518426A5 (https=) | ||
| JP2018508559A5 (https=) | ||
| KR100807480B1 (ko) | 피리베딜의 경비 투여용 약제 조성물 | |
| HK40087326A (zh) | γ-羟基丁酸衍生物的修饰释放组合物 |